SEC's $152M investor case, FDA's freeze-dried plasma, and FTC's health-data suit (July 27–August 2, 2026)
This week's digest tracks the SEC's RAD Diversified complaint, FDA's plasma license and BHT comment reopening, and FTC actions on health data, ticketing, and the IonQ–SkyWater review.
Scope and signal
This digest covers agency publication or update dates from July 27 through August 2, 2026. The week's useful pattern is concrete rather than thematic: the SEC put a $152 million retail-investor case on the docket; the FDA moved a room-temperature plasma product into the U.S. market while reopening a chemicals comment period; and the FTC paired a health-data complaint with a ticketing settlement and early termination of a semiconductor transaction review.
The official materials do not establish a causal share-price reaction for the named companies. For public-company exposure, the actionable signal here is the regulatory record, the procedural posture, and the work it creates for legal, compliance, quality, privacy, and transaction teams.
At a glance
| Agency and date | Action | Status and immediate follow-up |
|---|---|---|
| SEC, July 29 | Filed a fraud case against RAD Diversified REIT, its founders, and a related entity over an alleged $152 million retail-investment scheme. 1 | Complaint filed in federal court; relief is sought, not adjudicated. Review offering records, investor-fund tracing, redemption controls, and valuation support. |
| SEC, July 27 | Released its 45th Small Business Forum report to Congress, covering early-stage capital, growth-stage companies and smaller funds, and small-cap public markets. 2 | Policy report, not a new rule. Smaller issuers and funds should track which recommendations may become future rulemaking or staff priorities. |
| FDA, July 29 | Licensed Ezplaz, the first freeze-dried plasma product licensed in the United States, for adult transfusion when other plasma is unavailable. 3 | Vascular Solutions, a Teleflex subsidiary, holds the license. Hospitals and emergency-response buyers should work from the approved labeling and storage instructions. |
| FDA, July 29 | Reopened the BHT request-for-information comment period for food and food-contact uses. 4 | New deadline: August 31, 2026, Docket FDA-2026-N-2526. Map BHT use, supplier data, and safety evidence before deciding whether to comment. |
| FDA, July 29–31 | Announced FY2027 FSMA user fees, updated an E. coli frozen-berry investigation, and recorded an expanded Pluvicto approval. 567 | VQIP applicants must pay before October 1; businesses must remove recalled berries from commerce; Pluvicto teams should use the current prescribing information for label work. |
| FTC, July 27 | Elite Events and its operators agreed to pay $300,000 to resolve allegations that they bypassed ticket-purchase limits. 8 | Resolution under the Better Online Ticket Sales Act. Ticketing platforms and brokers should test controls against automated or coordinated limit evasion. |
| FTC, July 29 | The FTC, Utah, and California sued Hims & Hers over alleged sharing of sensitive health information with advertising platforms and deceptive billing and cancellation practices. 9 | Complaint stage; no monetary amount is used here because it was not verifiable from the readable release. Audit data flows, consent language, cancellation paths, and retention evidence. |
| FTC, July 31 | Granted early termination of its review of IonQ's proposed acquisition of SkyWater Technologies. 10 | FTC review ended early. The action does not by itself establish that every other closing condition has been satisfied. |
SEC: a new retail-investor case and a policy signal for smaller issuers
RAD Diversified: the complaint is the event, not a judgment
On July 29, the SEC sued RAD Diversified REIT, Inc., founders Brandon "Dutch" Mendenhall and Amy Vaughn, and The Seminar Solution, LLC, a related entity. The complaint alleges that the defendants raised at least $152 million from more than 5,500 retail investors from November 2019 through March 2024. It alleges that the founders misappropriated nearly $5 million and diverted about $54 million of investor funds to The Seminar Solution, including money later used for personal expenses. 1
The alleged sales story matters as much as the headline amount. The SEC says RAD was marketed as a profitable REIT, investors were told that no investor had ever lost money, and the company's rising stock price was attributed to independent property valuations. The complaint alleges that the properties were not independently valued, the stock price was not updated after July 2023, and redemption requests were routinely denied or ignored before RAD froze redemptions in February 2024 and filed for bankruptcy in March 2026. Those are allegations in a newly filed case, not findings after trial. 1
The SEC seeks permanent injunctions, disgorgement with prejudgment interest, civil penalties, conduct-based injunctions, and officer-and-director bars. The release does not state a final monetary award because there is no judgment yet. 1
For issuers, sponsors, and placement agents, the immediate review is documentary:
- tie every offering statement and investor presentation to dated valuation, liquidity, and redemption records;
- reconcile investor money to the stated use of proceeds and preserve the reconciliation history; and
- identify every claim about profitability, demand, appraisals, or investor outcomes that depended on a third party or internal model.
The practical market implication is exposure to litigation, funding pressure, and possible loss of investor liquidity—not a verified one-day stock-price move. RAD's release is a case filing; the court process is the next event to watch.
Small Business Forum report: useful direction, no immediate compliance deadline
The SEC's July 27 report to Congress summarizes recommendations from its 45th Annual Government-Business Forum on Small Business Capital Formation and the Commission's responses. The forum covered early-stage capital raising, growth-stage companies and smaller funds, and small-cap companies in public markets. The report is a policy record rather than a proposed rule, and the release supplies no comment deadline. 2
That distinction matters for planning. A smaller public company or fund does not have a new filing obligation from this release alone. Its next step is to read the report's recommendations and responses, then watch for a later proposal, exemptive action, or staff guidance that converts a policy discussion into a compliance requirement. The SEC says the report and the forum's video archives and transcript are available online. 2
FDA: room-temperature plasma, chemicals data, and product controls
Ezplaz changes the logistics of plasma availability
On July 29, FDA licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product licensed for use in the United States. FDA says it is intended for adult transfusion when plasma is needed and other plasma products are unavailable. The license holder is Vascular Solutions, LLC, a Teleflex subsidiary. 3
Ezplaz is derived from a single unit of fresh frozen plasma and is available in Group AB and Group A with low-titer anti-B blood types. Unlike conventional plasma, it can be stored at room temperature, reconstituted rapidly, and transported without a freezer-and-thaw workflow. FDA's stated use cases include combat zones, disasters, rural settings, and other austere environments. 3
The operational question is not whether the product is novel; it is whether a buyer can put the license into a controlled deployment plan. Hospitals, military medical units, emergency-response contractors, and distributors should check the approved labeling, storage controls, reconstitution procedure, blood-type limitations, training records, and lot traceability before treating room-temperature storage as a substitute for ordinary plasma procedures.
BHT: the comment clock is open again
FDA reopened the public-comment period for its request for information on butylated hydroxytoluene, or BHT, in human food and as a food-contact substance. The new deadline is August 31, 2026, in Docket FDA-2026-N-2526. FDA says it wants current-use information, safety data, scientific information, and comments as part of its post-market assessment of chemicals in food. 4
This is an information request, not a final ban or authorization change. Food manufacturers, ingredient suppliers, packaging companies, and trade groups should first map where BHT appears in formulations or food-contact materials, then identify the data that supports the use. A comment that cannot connect a use to a product, exposure, safety study, or supply-chain record will be harder to use than a short submission built around verified records.
Frozen berries: an immediate inventory action
FDA's July 30 update said it and CDC were investigating an ongoing multistate outbreak of E. coli O145:H28 linked to GreenWise organic frozen blueberries and mixed berries from Frutas y Hortalizas del Sur S.A. in Chile. Publix recalled all lots on July 29. The products were shipped to stores in Alabama, Florida, Georgia, Kentucky, North Carolina, South Carolina, Tennessee, and Virginia. 6
FDA's instructions are operational: businesses should not sell, serve, or use recalled product; remove it from sale; and clean and sanitize surfaces and containers that it touched. FDA also says affected products from the firm were added to Import Alert 99-35, allowing detention without physical examination. 6
Retailers and food-service operators should check inventory, receiving records, store-level withdrawals, repackaging, and sanitation logs. Because the FDA page distinguishes the July 29 Publix recall from an earlier July 3 single-lot recall, teams should not rely on a product name alone; match package size, UPC, lot, and best-by information to the recall notice. 6
Two approval and fee items with different deadlines
FDA's oncology approval-notification page records a July 31 approval of lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto by Novartis, in combination with androgen receptor pathway inhibitor therapy for adults with PSMA-positive metastatic androgen pathway modulation-naive or -sensitive prostate cancer. FDA notes that the condition was previously referred to as metastatic hormone-sensitive prostate cancer. The approval-notification page is a record of the action; label, safety, and promotional teams should use the current prescribing information for the exact approved language. 7
On July 29, FDA also announced FY2027 user fees for the Voluntary Qualified Importer Program and the Accredited Third-Party Certification Program under FSMA. Approved VQIP applicants must pay the user fee before October 1, 2026 to receive FY2027 benefits. The third-party certification fee rate also takes effect October 1. 5
The two items call for different internal owners. Pluvicto affects label, medical, regulatory, and commercial review. VQIP and third-party certification affect importer and certification-program budgets. Neither should be handled as a generic "FDA update."
Warning-letter index: this week's entries were closeouts
The FDA warning-letter pages posted during the window included closeout letters for MedisourceRx and Similasan AG, rather than new warning letters alleging fresh violations. FDA said MedisourceRx had adequately addressed the violations in its December 2025 warning letter, while Similasan had addressed violations in a September 2023 warning letter. Both letters preserve FDA's ability to take future action if later inspections or other evidence show violations. 1112
For quality teams, a closeout is not a permanent safe harbor. It is evidence that FDA evaluated the cited corrective actions favorably at that point. Keep the corrective-action file, effectiveness checks, and ongoing compliance monitoring intact.
FTC: health-data controls, ticket limits, and a transaction review ending
Hims & Hers: the complaint reaches beyond privacy notices
On July 29, the FTC, joined by Utah and California through Los Angeles County Counsel, sued Hims & Hers. The official case description says the complaint alleges that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming to maintain consumer privacy. It also alleges deceptive billing and cancellation practices. 913
This is a complaint-stage case. The FTC case page lists the filed complaint and its July 29 date, but the readable release does not provide a monetary figure that can be safely used here. The right compliance response is therefore not to reverse-engineer a penalty; it is to preserve the evidence that would explain the data flow and customer journey: advertising-platform disclosures, consent and authorization language, health-data inventories, billing records, cancellation tickets, and retention schedules.
The allegation also illustrates why a privacy notice is not the whole control. If product analytics, ad pixels, customer-support workflows, or cancellation design operate differently from the promise made to a patient, the enforcement risk can sit in the gap between the notice and the system.
Elite Events: ticket limits are a control problem
On July 27, the FTC announced that ticket broker Elite Events and its operators would pay $300,000 to resolve allegations that the company purchased millions of dollars of tickets and bypassed ticket-purchase limits in violation of the Better Online Ticket Sales Act. The proposed resolution also bars the unlawful tactics described by the agency. 8
Ticketing businesses should treat purchase limits as a system rule, not a sentence in the terms of sale. That means testing account creation, payment instruments, device and IP signals, reseller relationships, bot controls, exception handling, and audit logs. The FTC release supplies a compliance direction even for firms that are not named: a limit that can be bypassed at scale is not much of a limit.
IonQ/SkyWater: early termination is procedural, not a universal clearance
On July 31, the FTC announced the early termination of its investigation of IonQ's proposed acquisition of SkyWater Technologies. The action ends the FTC's review of that transaction, but it does not say that every other regulatory, financing, shareholder, or contractual closing condition has been satisfied. 10
For deal teams, the next step is to update the closing checklist with the FTC status while keeping the remaining conditions separate. For investors, the agency announcement is a procedural development; it is not a verified measure of the transaction's eventual economics or of a share-price reaction.
Dates to put on the calendar
| Date | Item | Action |
|---|---|---|
| August 31, 2026 | FDA BHT request for information | Submit data and comments in Docket FDA-2026-N-2526 if BHT use, food-contact materials, or relevant safety evidence falls within your business. 4 |
| Before October 1, 2026 | FDA FY2027 VQIP user fee | Approved VQIP applicants should pay before the program year begins if they want FY2027 benefits. 5 |
| October 1, 2026 | FDA FY2027 TPP fee rate | Budget for the new third-party certification rate and confirm the program's payment and participation instructions. 5 |
| Immediate | GreenWise frozen-berry recall | Stop sale, service, and use; reconcile lots and complete sanitation and withdrawal records. 6 |
The next monitoring pass should start with the RAD Diversified docket, the Hims & Hers case documents, and any FDA action that changes the BHT comment record or frozen-berry investigation. The recurring distinction remains important: a filed complaint is not a judgment, a closeout letter is not a new warning letter, and early termination of one agency review is not blanket transaction clearance.
References
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11MedisourceRx Closeout Letter
fda.gov
- 12Similasan AG Closeout Letter
fda.gov
- 13Hims & Hers FTC case page
ftc.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.